Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash

Swiss drugmaker Novartis raised its full-year sales outlook and announced on Thursday the $2.1 billion acquisition of U.S. biopharmaceutical company Endocyte.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.